The Xigris saga isn't over yet --- our criticism of PROWESS might have been substantiated by further developments. The more recent Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS), Resolution of Organ Failure in Pediatric Patients with Severe Sepsis (RESOLVE) and the Extended Evaluation of Recombinant Human Activated Protein C (ENHANCE) studies heighten our concerns, underlining the bleeding risk associated with use of drotrecogin alfa.
The most telling recent commentary is a recent Perspective in the New England Journal of Medicine (N Engl J Med. 2006 Oct 19;355(16):1640-2), which fairly discusses the ongoing concerns about rhAPC, and Lilly's marketing strategies including the `Surviving Sepsis' campaign.
| Date of First Publication: 2006/10/18 | Date of Last Update: 2006/10/28 | Web page author: Click here |